Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome

Pediatric Nephrology

Volumn 28, Issue 9, 2013, Pages 1875-1879

  Sellier Leclerc, Anne Laure ^a   Belli, Emre ^b   Guérin, Valérie ^c   Dorfmüller, Peter ^b   Deschênes, Georges ^c,d  

^a HOSPICES CIVILS DE LYON   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

B cell depletion; Fulminant myocarditis; Hypogammaglobulinemia; Idiopathic nephrotic syndrome; Rituximab

Indexed keywords

AMOXICILLIN; COTRIMOXAZOLE; CYCLOSPORIN A; DEXCHLORPHENIRAMINE; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEVAMISOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ANTIBIOTIC THERAPY; ARTICLE; CARDIOGENIC SHOCK; CASE REPORT; CHILD; CHILDHOOD DISEASE; DRUG INDUCED DISEASE; DRUG MEGADOSE; ELECTROCARDIOGRAM; ENTEROVIRUS; EXTRACORPOREAL OXYGENATION; FLOW CYTOMETRY; FOLLOW UP; HEART GRAFT; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATORY INFILTRATE; MALE; NEPHROTIC SYNDROME; NEUTROPENIA; OTALGIA; PEDIATRIC SURGERY; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; PREMEDICATION; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; VASCULITIS; VIRUS MYOCARDITIS;

EID: 84881083944     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2485-9     Document Type: Article

References (26)

1. Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: A multicentric series of 22 cases. Pediatr Nephrol 23:1269-1279
2. Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321-1328
3. Sellier-Leclerc AL, Macher MA, Loirat C, Guérin V, Watier H, Peuchmaur M, Baudouin V, Deschênes G (2010) Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 25:1109-1115
4. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, Srivastava RN, Moudgil A, Bagga A (2010) Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: Multicentric report. Clin J Am Soc Nephrol 5:2207-2212
5. Prytula A, Iijima K, Kamei K, Geary D, Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, Ognjanovic M, Filler G, Smith G, Tullus K (2010) Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 25:461-468
6. Sellier-Leclerc AL, Baudouin V, Kwon T, Macher MA, Guérin V, Lapillonne H, Deschênes G, Ulinski T (2012) Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant 27(3):1083-1089
7. Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber L, Pohl M, Rosenthal K, Rosahl A, Mueller-Wiefel DE, Dötsch J (2012) Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 27(5):1910-1915
8. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis. Arthritis Rheum 56(12):3896-3908
9. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753-1755
10. Kamei K, Ito S, Iijima K (2010) Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 5(6):1193
11. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: A review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10:816-824
12. Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145-149
13. Bhatt GC, Sankar J, Kushwaha KP (2012) Use of intravenous immunoglobulin compared with standard therapy is associated with improved clinical outcomes in children with acute encephalitis syndrome complicated by myocarditis. Pediatr Cardiol 33:1370-1376
14. Ardelean DS, Gonska T, Wires S, Cutz E, Griffiths A, Harvey E, Tse SM, Benseler SM (2010) Severe ulcerative colitis after rituximab therapy. Pediatrics 126:e243-246
15. Sailler L (2008) Rituximab off label use for difficult-to-treat auto-immune diseases: Reappraisal of benefits and risks. Clinic Rev Allerg Immunol 34:103-110
16. Marotte H, Paintaud G, Watier H, Miossec P (2008) Rituximab related late-onset neutropenia in a patient with severe rheumatoid athritis. Ann Rheum Dis 67:893-894
17. Cooper N, Arnold DM (2010) The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol 149:3-13
18. Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, Schlesier M, Voll RE, Thiel J (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 7(5):e37626
19. De La Torre I, Leandro MJ, Valor L, Becerra E, Edwards JC, Cambridge G (2012) Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: Relationship with B-cell kinetics. Rheumatology (Oxford) 51(5):833-840
20. Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, Kumano K, Minauchi K, Koike T (2005) Persistent pan-hypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol 75:527-529
21. Walker AR, Kleiner A, Rich L, Conners C, Fisher RI, Anolik J, Friedberg JW (2008) Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest 26:431-433
22. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-473
23. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC (2006) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 54:723-732
24. Cooper N, Davies EG, Thrasher AJ (2009) Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 146:120-122
25. Besada E, Bader L, Nossent H (2011) Sustained hypogammaglobulinemia under rituximab maintenance therapy could increase the risk for serious infections: A report of two cases. Rheumatol Int. doi: 10.1007/s00296-011-2353-5
26. Otremba MD, Adam SI, Price CC, Hohuan D, Kveton JF (2012) Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia. Am J Otolaryngol 33(5):619-622